Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Thornton & Ross Ltd., Linthwaite, Huddersfield, HD7 5QH, UK
Paroven capsules 250 mg.
| Pharmaceutical Form |
|---|
|
Capsules. |
Active ingredient: Oxerutins 250 mg.
| Active Ingredient | Description | |
|---|---|---|
| Rutoside |
|
|
| Troxerutin |
The pharmacodynamic effects of oxerutins have been demonstrated in different in vitro and in vivo studies. At the cellular level the capability of oxerutins to protect the vascular wall from the oxidative attack of activated blood cells and its affinity to the endothelium of capillaries and venoles could be shown. |
| List of Excipients |
|---|
|
Polyethylene glycol |
Blister pack composed of PVC blisters sealed with aluminium foil.
Blister pack composed of PVC/PE/PVDC blisters sealed with aluminium foil.
Pack sizes: 120 capsules.
Thornton & Ross Ltd., Linthwaite, Huddersfield, HD7 5QH, UK
PL 00240/0550
First Authorisation: 19 July 1991
Date of renewal: 28 March 2011
| Drug | Countries | |
|---|---|---|
| PAROVEN | United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
